Please accept my apologies for the time it has taken me to contact you with a decision on your manuscript. It took me some time to secure referees for this study and then unforeseen circumstances led to the tardiness of one of the referee reports. The study has been assessed by two experts (see their reports below), both of whom are positive about the suitability of the study for EMBO reports but request that several important controls be provided and several issues clarified before the manuscript could be considered for publication.
One formal concern that I share with referee 2 is that the study is not written in a manner that is accessible to a general readership, and this issue also has to be addressed. As EMBO reports publishes short-format studies, the manuscript length would need to be considerably reduced to a maximum of 30,000 characters, including spaces and references. The presentation of a merged results and discussion section would help to eliminate some redundancy inherent to describing them separately. Please also note that materials and methods essential to the understanding of the experiments performed need to be included in the main text; more detailed explanations required to reproduce the experiments can be presented as supplementary information. In addition, we can publish a maximum of 5 figures in the main text, but only repetitions or control experiments may be presented in the supplement. Please retain the figures that prove the main message of the study in the main text.
If the referee concerns can be satisfactorily addressed, we would be happy to consider your study for publication. Please note that revised manuscripts must be submitted within three months of a request for revision unless previously discussed with the editor; they will otherwise be treated as new submissions.
I look forward to seeing a revised form of your manuscript when it is ready.
Yours sincerely, Editor EMBO Reports REFEREE REPORTS:
Merzougui et al. address a critical issue in the antigen processing and presentation field: how do indirect effects from inhibiting TAP or proteasomes affect cross-presentation.
This question was first raised by Harding and colleagues, who showed that knocking out TAP or tapasin indirectly affected cross-presentation by reducing class I trafficking, and that this could be reversed by incubation at 26 C (the latter point should be mentioned by the authors) . Although the work of Harding et al. is quite clear and compelling (and is referred to by the authors; though they should also refer to Song and Harding, JI, 1996) , the antigen processing field exhibits collective amnesia to the extent where a good shaking is desperately needed to reacquaint its practitioners to the practical limits of interpreting TAP and proteasome blockade.
This effort from Merzougui et al., therefore is a welcome study with the potential to positively impact the field permanently. Much of the paper is outstanding, and there a many novel aspects (including the use of trypsin to remove unfolded class I molecules, which will also give pause to those who use trpysinized cells for cross-presentation). That being said, it is critical that Merzougui et al. do a thorough job of debunking. I have a number of suggestions for strengthening this fine study.
Major comments 1. My take on the author's understanding of the effect of TAP k/o on class I trafficking, is that they believe that as originally proposed by Ploegh and colleagues, class I molecules are retained in the ER at 37{degree sign}C in TAP negative cells (RMA/S), and then "come out in the cold" (at 26{degree sign}C ). Day et al, (Immunity, 1995) however, clearly established via labeling with tritiated galactose that class I trafficking through the Golgi complex occurs at a rate identical in RMA/S and RMA (TAP + cells) at 37{degree sign}C. Rather, the effect of low temperature is to stabilize class I molecules at the cell surface). These findings extended the prior publication of Ortiz-Navrette and Hammerling (PNAS, 1991) describing the use of mAbs to trap nascent class I molecules in their native conformation to prevent unfolding and degradation upon reaching the surface of RMA/S cells. Coming out in the cold vs. simply being stabilized by the cold is an important distinction, and while it is possible that the rules differ in DCs, there is no evidence presented to this effect, and if the authors wish to dispute this conclusion, they should directly do so by experimentation. 2. Day et al. introduced the use of fluorescent tagged SIINFEKL (the K is derivatized) to measure peptide-receptive Kb ("empty" by other terms). This could easily be applied by the authors to measure the amount of peptide-receptive class I molecules expressed on the cell surface and intracellularly (SIINFEKL-FL also binds class I molecules post-fixation). Alternatively, 25-D1-16 can be used for this purpose after pulsing with unlabelled SIINFEKL (but doesn't work for intracellular Kb). In parallel, the authors could measure β2m binding to free heavy chains as originally described by Rock and Benacerraf in a series of 5 papers between 1990-1995. All of these measurements will help define the nature of class I molecules that participate in cross-presentation. This work is not redundant, since first, the connection with cross-presentation has never been made, and second, DCs have not been previously studied (from our own unpublished results, DCs have a far lower fraction of peptide receptive/total conformed Kb molecules than the tumor cells published previously. 3. Figure 6 shows an elegant experiment designed to test the effects of proteasome inhibitor modulation of Ub metabolism on cross-presentation. But what about the effects of proteasome inhibitors on the supply of fully native and peptide receptive class I molecules? It is important to examine the effect of proteasome inhibition on class I trafficking as performed for TAP knock out cells and as suggested in points 1 and 2 above. Technical comments 1. What is the background staining of acid-trypsin treated cells? Two controls would be useful. Acid-trypsin treated non class I expressing cells tested with the same mAb and a different mAb used to stain the experimental groups. 2. Background levels of IL-2 secretion in the various experiments?
Referee #2:
Merzoughi et al. report on a MHC class I cross-presentation pathway in bone marrow-derived dendritic cells that is TAP-independent, proteasome-dependent, accentuated in TAP-/-cells by preincubation at 26oC and apparently restricted to particulate antigen. The work is important as the mechanisms underlying cross-presentation are of obvious clinical relevance and continue to be hotly debated. Also on the positive side is the meticulous, systematic approach that the authors use to argue for the existence of this unique, perhaps counterintuitive pathway. I have two major concerns: 1) First, the argument is fairly challenging to follow, involving indirect assessments of class I behavior in the absence of TAP at 37oC and 26oC (monoclonal reactivity, acid elution, trypsin sensitivity, internalization), and a variety of chemical inhibitors, some yielding anticipated results, some not. Thus, one concern is the extent to which many biomedical scientists, even immunologists, will be able to follow the thread. To a great degree there is not much that can be done about this. My one suggestion is that the authors consider a companion schematic figure for the discussion that brings together the various key observations. 2) Second, while many results are presented, there are two panels that are of particular importance. a. Figure 2 , panel B. In TAP-/-cells, this pathway becomes apparent at 26oC because class I molecules are preserved and delivered to endosomes. Figure 7 suggests that trafficking of these class I molecules is similar to those from wild-type mice. Nevertheless, the monoclonal antibody reactivity and acidification/trypsin experiments indicate that the cohorts are fundamentally different. If they are indeed loaded with peptide, the loading is unconventional and the peptides may be much more easily exchanged than those that are loaded under TAP+/+ conditions. A key question, therefore, is how much the TAP-independent pathway is utilized in wild-type cells at physiological temperatures, and panel B ostensibly shows that approximately half of the presentation from either particulate antigen (coated beads or yeast) is TAP-independent. However, what I can't tell from the description of the experiment, although this is implied in the discussion, is whether negative controls have been subtracted. It will not be helpful to the case laid out by the authors if the no antigen controls are at the same levels as the TAP ko/37oC samples. b. Figure 6 . The conclusion that the pathway is proteasome dependent depends upon the use of inhibitors that could indirectly impact antigen processing/presentation. Three controls address this. First, presentation of synthetic peptide is not affected but this is really an assessment of T cell, not APC, function. Second is the use of a vaccinia expressed minigene ( Figure 5A ). This is not an ideal control because the amount of epitope derived from this construct is much higher than that from full-length protein such that there could be potent inhibition of presentation from the minigene construct and still maximal T cell stimulation. To a great extent, this concern could be alleviated by the experiment in Figure 6 but here is the same potential problem as with the minigene construct. The amount of input antigen (yeast-ova peptide) could well be, and appears to be, supersaturating. I would like to see this experiment done with titrating amounts of input antigen. The proteasome inhibitors should have no impact at doses of antigen that induce submaximal stimulation. Items of lesser concern: 1) The primaquine experiment, showing enhancement of presentation via this pathway, is counterintuitive and deserves more direct consideration. The result suggests that class I molecules enter and are loaded with peptide in a recycling compartment but do not transit from there to the cell surface. If there were fusion with phagosomes, as suggested in the discussion, would trafficking from this compartment to the cell surface be unaffected by primaquine? Is this known? 2) Likewise, the inhibition by Z-FA-fmk of SL8 presentation from the fusion protein is fairly substantial but this is not discussed much. Has this been observed in other cross-presentation systems? What is the supposed mechanism and when is the action, before delivery to the cytosol or after transfer to the loading compartment? 3) For the temperature shift experiments, I could not figure out how antigen was added. Was this at the end of incubation at 26oC and before shift to 37oC? Was there a specific period of time of antigen exposure and then wash out? More detail in the figure legend and/or the Materials and Methods would be helpful. 4) Tracing the fate of antigen (Figure 7) would be of limited value in discerning information about similarities and differences in processing pathways if a cytosolic/proteasomal step is required. We would like to thank the reviewers for their constructive and overall positive criticism, which has allowed us to ameliorate the paper. In revising the paper, we were guided next to the desire to respond to all criticisms and therefore add and discuss more experimental evidence, by the necessity to reduce the size of the manuscript by more than 50 percent. Because of this, the discussion of the data had to be limited to the essential.
POINT-BY-POINT REPLIES REVIEWER 1
The reviewer suggests citing a second reference from the Harding laboratory (Song and Harding, JI 1996) . Reply: because of severe space constraints, we are unable to respond to this request (each citation adds an average of 170 characters without a single word of discussing it).
The reviewer points out that previous evidence published in Immunity and PNAS shows that low temperature results in stabilization at the cell surface rather than increased export of class I molecules by TAP-deficient RMA-S cells, and suggests that, unless experimental evidence shows that the situation is different in DC, we replace the concept of class I molecules "coming out in the cold" by the concept of stabilization.
Reply: we agree that, although we can show that DC class I molecules are not stabilized by exogenous ß 2-m (see below), we do not have evidence supporting the concept of increased export rather than stabilization at the surface. We have therefore changed the wording and interpretation at the relevant places (page 5 center, page 7 top).
The reviewer suggests performing additional characterization of cell surface class I molecules using a fluorochrome-labeled peptide epitope and exogenous sources of ß 2-m, following protocols published by the Yewdell and Rock laboratories.
Reply: we have performed the suggested experiments (Fig. 1D, E) , with some interesting results. First, in contrast to published results obtained with RMA-S cells, both TAP deficient and wild type DC seem to express very little peptide-receptive cell surface class I molecules, and the rate of such molecules does not differ significantly between the two DC types (Fig. 1D) . Second, we find that the published requirement of exogenous ß 2-m for increased class I cell surface expression at 26°C applies only to conditions of cell starvation and disappears when protein-and ß 2-m-free-media that are sufficiently complete to support cell growth are used (Fig. 1E ). This finding removes one direct argument supporting the concept of stabilization rather than increased export of class I molecules (see previous point), however as the data published by Day et al directly demonstrate equivalent export of class I molecules by wt and TAP ko DC, we still adopted the concept of cell surface stabilization. Our interpretation is that low temperature most likely reduces class I internalization and degradation.
The reviewer suggests that we test the effect of proteasome inhibitors on the number, conformation and peptide-receptive state of cell surface class I molecules. Reply: we have performed these experiments and observed that short-term incubation with proteasome inhibitors (as used in antigen presentation experiments) has no effect on any of these parameters. Because of space restrictions we do not show these results which are mentioned on page 10 (top) and can be produced to the reviewers if required.
The reviewer asks what the background staining of acid-trypsin treated cells was.
Reply: isotype control staining values are now mentioned in the legend to Fig. 1C .
The reviewer requests providing details about the background of IL-2 secretion.
Reply: this information has now been inserted in the methods (section Antigen presentation assays, page 13). Background was subtracted in all figures except 4B.
REVIEWER 2.
The reviewer points out that the argument is somewhat difficult to follow and suggests adding a figure summarizing the key points of the paper. Reply: we have added Fig. S2 that summarizes the key findings and proposes an alternative model for cross-presentation of phagocytized antigen. We hope that shortening the paper and merging results and discussion also has simplified the argument.
The reviewer requests indicating background T cell responses in cross-presentation assays and detailing whether background values were subtracted, insisting that this is important to assess whether the putative TAP-independent pathway is indeed relevant at physiologic temperature.
Reply: we now indicate background values in the Methods section (page 13 center; see also replies to reviewer 1) and detail that these values have indeed been subtracted in all figures but Fig. 4B . Considering this information, it is clear that TAP ko DC display retain significant cross-presentation capacity at physiologic temperature. Importantly, the extent of this presentation is proportional to the extent of class I expression at 37°C. Fig. 6 ), and suggests a titration experiment. Reply: indeed this is a valid and important concern, and we have performed the requested experiment. As shown in the new panel, presentation of yeast-S8L remains proteasome-independent at non-saturating antigen amounts, as shown in the new Fig. 5D (one out of three experiments performed).
The reviewer contends that the amount of yeast-S8L antigen could be supersaturating (experiment in original
The reviewer asks whether literature data on the primaquine dependence of MHC class I trafficking from phagosomes to the cell surface is available. Reply: we asked the same question when we observed the unexpected increase of cross-presentation in the presence of primaquine. Surprisingly, we did not find any pertinent data in the literature. However, due to severe space limitations, we are unable to discuss this issue in the present version of the manuscript.
The reviewer observes that the effect of cathepsin inhibitors on cross-presentation is little discussed, and asks about the putative mechanism.
Reply: we cite one recent experimental system in which very similar dependence on both the proteasome and cathepsins was observed (Singh and Cresswell publication in Science). There are a few more examples in the literature, which we are unable to cite or discuss in the paper because of space limitations. In none of these examples including the work of Singh and Cresswell, the mechanism and sequence of the involvement of the different proteases has been clarified.
The reviewer requests clarification about the time point at which antigen was added.
Reply: antigen was added at the time of shifting temperature to 37°C. This is now clarified in the Methods section (page 13).
The reviewer contends that tracing the fate of antigen is of limited value given that a cytosolic processing step is required. Reply: we agree with this point and have removed Fig. 7 that did not make a significant contribution to the conclusions of the paper.
The reviewer notes absence of an explanation of the means graph in Fig. 2B . Reply: we have clarified the legend for this panel. The confusion likely resulted from a mislabeling of the y-axis of this graph that should have read "Percent of control" rather than OD IL-2.
The reviewer criticizes a discrepancy between the order of the figures and the data. Reply: we have checked this and hope to have corrected the problem.
The reviewer notes various typographical errors.
Reply: these errors have been corrected.
2nd Editorial Decision 26 August 2011
Thank you for so thoroughly revising your study to address the referee reports and conform to EMBO reports format. I have now received the reports from the two referees who assessed the original version of your study. As you will see from the reports below, both referees are now positive about its publication here. Hence, I will be happy to accept your manuscript for publication once some minor issues have been addressed, as follows.
I have noticed that some figures present error bars without indicating in the legend the number of experiments performed and the nature of the error bars displayed (standard deviation, standard error, other). This occurs in some panels of figures 2, 3, 4, 5 and supplementary figure 1. Please go through these figure legends carefully and add this information were appropriate. Please also note that it is only statistically correct to present error bars when experiments have been performed three or more independent times.
In addition, I strongly feel that supplementary figure 2 should be included in the main text, as it will be very helpful to understand the message of the study (as you mention in your cover letter). I would suggest to combine figures 3 and 4, as they are related and rather small, and present SF2 as figure 5. In order to do this, however, the figure legend would have to be shortened considerably (you are welcome to refer the readers to the text for further details).
As a standard procedure, we edit the title and abstract of accepted studies to make them more accessible to a general readership. In this case, I think the title is good but have edited the abstract in some depth and have some queries to you where I am unsure of having maintained the meaning (please see below). Please read the edited version carefully and let me know if you do not agree with any of the changes.
Once you have made these minor revisions, please upload the final version of your manuscript through our online system.
If all remaining concerns have been attended to, you will then receive an official decision letter from the journal accepting your manuscript for publication in the next available issue of EMBO reports. This letter will also include details of the further steps you need to take for the prompt inclusion of
